Rotigotine: A novel dopamine agonist for the
transdermal treatment of Parkinson's disease
by
Zareba G.
Department of Environmental Medicine,
University of Rochester,
School of Medicine and Dentistry,
Rochester, New York, USA.
grazyna_zareba@urmc.rochester.edu.
Drugs Today (Barc). 2006 Jan;42(1):21-8.

ABSTRACT

Rotigotine is a D3/D2/D1 dopamine agonist delivered through a silicone-based transdermal patch that is administered once daily. Pharmacokinetic data in humans have shown that steady-state plasma levels of rotigotine can be reached between 8 and 12 hours, and a stable drug release is maintained throughout the 24-hour patch application. Results of several clinical trials demonstrated that the rotigotine transdermal system is safe, well tolerated and effective monotherapy for patients in the early stages of Parkinson's disease. Rotigotine transdermal application also demonstrated the possibility of decreasing levodopa dosage in order to decrease its toxic effects in advanced Parkinson's disease. In addition, rotigotine has shown efficacy in the treatment of restless legs syndrome. Clinical studies on rotigotine, the first transdermally delivered dopamine agonist, are now in progress, and regulatory approval is expected in the near future.

Rotigotine
Selegiline
Rasagiline
Bromocriptine
Parkinson's disease
Pramipexole (Mirapex)
Cabergoline (Dostinex)
Pramipexole and ropinirole for bipolars
Rotigotine (Neupro) in Parkinson's disease
Parkinson's disease: resources and hotlinks

HOME
HedWeb
Future Opioids
BLTC Research
Utopian Surgery?
The Hedonistic Imperative
MDMA: Utopian Pharmacology

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family